As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...

R&D innovation is likely to remain a major focus area in 2025 . M&A activity is also expected to remain strong, particularly with Trump’s return to the White House.Regular pipeline setbacks, slow ramp ...

POOR PIERRE — Mere months ago, the Conservative Party in Canada looked headed towards a landslide victory. Its leader, Pierre Poilievre, was ascendant and drawing rave reviews from much of the ...

Me's drugs and patents — including two possible deals — could be key to its exit out of Chapter 11 bankruptcy protection.

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...